Warm-toned photograph of a stethoscope resting on a wooden desk beside medical charts, conveying a serious healthcare setting

A national public affairs campaign launched by the American College of Cardiology in December 2009 to oppose Medicare physician fee schedule cuts affecting cardiology patients and practices.

About the Campaign

The Campaign for Patient Access was launched by the American College of Cardiology in December 2009 as a national effort to reverse Medicare physician fee schedule cuts that threatened cardiovascular care. The site provided background on the issue, the ACC's legislative and legal response, resources for patients and practices, a newsroom tracking coverage across the country, and ways for supporters to share their stories and support the campaign.

From the Newsroom

Capitol building dome against a pale sky, conveying federal policy and legislative action
April 30, 2010

Medicare Meltdown: Access to Health Care in "Critical Condition"

A press release warning that cardiology access was in critical condition due to Medicare payment cuts.

Read more
Gavel on a dark wooden bench in a courtroom setting, suggesting legal proceedings
December 29, 2009

Cardiology Takes Legal Action Against Medicare

The ACC filed suit against HHS Secretary Kathleen Sebelius over the 2010 Physician Fee Schedule.

Read more
A stack of newspapers with a muted gray and off-white palette, suggesting breaking health policy news
January 12, 2010

ACC Statement on Health Care Reform

The ACC used the State of the Union address to highlight the need to reverse the Medicare cuts.

Read more
A wide shot of a diverse group of healthcare professionals and advocates gathered around a conference table, deep in discussion
April 12, 2010

Medicare Patients and Physicians Join Petition Drive

Patients and physicians in Washington, DC joined a petition drive calling on Congress for Medicare reform.

Read more

When Fee Pressure Limits Advanced Lipid Testing Access

Cardiovascular risk assessment is becoming more precise. A standard cholesterol panel remains central to prevention, yet tests such as apolipoprotein B (ApoB), lipoprotein(a) [Lp(a)], LDL particle measures and familial hypercholesterolaemia testing can reveal risk that ordinary results may miss. These tools are especially relevant for people with premature coronary disease, diabetes, high triglycerides or a strong family history.

The concern is that clinical value does not guarantee practical access. When physician payments fall, cardiology practices and pathology providers must absorb higher staffing, equipment, compliance and information technology costs while receiving less for professional work. Testing that requires specialist interpretation, follow-up and shared decision-making can be particularly vulnerable.

The American College of Cardiology’s Campaign for Patient Access highlighted how Medicare physician fee schedule cuts in the United States could affect cardiovascular services. Australia operates through a different system, with Medicare Benefits Schedule rebates, private fees, state-funded hospitals and mixed pathology arrangements. The underlying lesson still matters locally: payment pressure can alter which services are offered, where they are available and how quickly patients receive them.

For Australians, the impact may appear as a longer wait for a cardiology appointment, a larger out-of-pocket bill or a decision to rely on a basic lipid profile when a more detailed assessment would be useful. In rural and outer-metropolitan areas, reduced service capacity can also mean travelling several hours for a test or specialist review.

Why Advanced Lipid Testing Matters

A routine lipid panel usually reports total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Those measures support established treatment decisions, but they do not describe every aspect of a patient’s atherogenic particle burden. ApoB estimates the number of cholesterol-carrying particles, while Lp(a) identifies an inherited risk factor that is largely independent of standard LDL cholesterol.

This additional information can help clinicians interpret apparently reassuring results. Someone with controlled LDL cholesterol may still have elevated Lp(a), high ApoB or a pattern of triglyceride-rich particles associated with residual cardiovascular risk. The result may influence the intensity of lifestyle support, statin therapy, additional lipid-lowering treatment or screening of relatives.

Advanced testing is not automatically appropriate for everyone. Clinical context, family history, kidney function, diabetes status, previous cardiovascular events and current treatment all matter. A test is useful when its result changes management or improves risk discussion; it is less useful when it adds expense without affecting care.

That distinction makes access to qualified interpretation essential. A pathology result without a clear explanation can create anxiety, unnecessary repeat testing or false reassurance. Cardiologists, lipid specialists, GPs and genetic counsellors may need time to connect the result with the patient’s broader risk profile.

How Fee Pressure Travels Through Care

A fee cut rarely affects just the line item on a medical invoice. It can reduce the time available for a consultation, make complex follow-up less attractive and encourage practices to prioritise services that are financially sustainable. Advanced lipid assessment often involves reviewing previous results, confirming indications, explaining inherited risk and arranging repeat monitoring, so it may be more exposed than a straightforward appointment.

Lower reimbursement can also affect investment in clinical systems. Practices may delay upgrades that support electronic pathology integration, population recall for high-risk patients or secure sharing of results with GPs. These changes may seem administrative, yet they influence whether an abnormal Lp(a) result is acted upon or simply filed.

Pathology access can be affected through a separate pathway. In Australia, many routine tests are covered under the MBS when they meet the relevant criteria, while other specialised assays may have limited rebates or be privately billed. Patients may face different charges depending on the test, provider, referral pathway and whether the service is delivered in a public hospital, private clinic or community collection centre.

When professional fees and pathology funding are both under strain, the result can be a fragmented service. A patient may receive a test through one provider, discuss it with a GP who has limited appointment time and wait weeks for a specialist opinion. This is a system access problem, rather than a failure of patient motivation.

Australian Access Realities

Australia’s geography makes service reductions particularly visible. A person in regional New South Wales may need to travel to Newcastle or Sydney for a lipid specialist, while someone in northern Queensland may face a long trip to Brisbane. In Western Australia, the distances from Perth to regional communities can make repeated specialist appointments difficult, especially for older people or those without reliable transport.

Telehealth can reduce some travel, but it cannot replace every pathology collection, physical assessment or genetic counselling appointment. The Royal Flying Doctor Service and visiting specialist clinics provide vital support in remote areas, although their capacity is finite. If fewer cardiologists, endocrinologists or lipid services accept complex referrals, local GPs carry more responsibility for interpretation and follow-up.

Cost is another practical issue. Australians commonly talk about whether a visit is “bulk-billed” or involves a gap, and that gap can determine whether a patient proceeds with a recommended test. A household managing rent, medicines and travel expenses may postpone a privately billed ApoB, Lp(a) or genetic test, even when the clinician believes the result would clarify risk.

Public hospitals may provide advanced assessment for eligible patients, but waiting lists and referral requirements vary between states and health services. Private care may offer faster access, yet fees differ considerably. These differences mean that postcode and income can influence the likelihood of receiving personalised lipid evaluation.

Who Faces the Greatest Risk

People with suspected familial hypercholesterolaemia are among those most likely to be affected by limited access. Early heart attacks in close relatives, very high LDL cholesterol, tendon xanthomas or a strong pattern of premature disease may justify specialist assessment and cascade screening. Identifying affected relatives can support earlier treatment across an entire family.

Patients with established coronary artery disease, diabetes, chronic kidney disease or persistently high triglycerides may also benefit from a more detailed review. In these groups, treatment decisions often depend on the relationship between several risk factors rather than a single cholesterol number. A fee-driven reduction in consultation time can make that assessment harder.

Aboriginal and Torres Strait Islander communities may experience additional barriers linked to distance, culturally safe care, workforce shortages and fragmented follow-up. Patients in outer suburbs and regional towns can face similar problems when specialist services are concentrated in capital cities. A uniform policy may therefore produce unequal effects across communities.

The following comparison illustrates how funding pressure can shape the patient journey. It is a practical framework rather than a substitute for checking current MBS rules, private fees or local referral requirements.

Care element When access is well supported When fee pressure is high
Specialist assessment Time to review family history, treatment and advanced results Shorter consultations or delayed referrals
ApoB or Lp(a) testing Ordered for a clear clinical purpose with explained results Deferred because of uncertain rebate or patient cost
Familial hypercholesterolaemia review Genetic or clinical assessment with family follow-up Limited cascade screening and missed relatives
Regional care Visiting clinics, telehealth and coordinated pathology Long travel to Sydney, Perth, Brisbane or another hub
Ongoing monitoring Recall systems and communication with the GP Results handled inconsistently or follow-up postponed

Practical Ways To Protect Access

Patients and clinicians can support fairer access by making the clinical value of advanced lipid testing visible and by documenting where financial barriers interrupt care. Useful steps include:

  • Ask whether the proposed test is covered by Medicare, privately billed or subject to a gap, and request an estimate before collection.
  • Record family history of early heart attack, stroke, very high cholesterol and known Lp(a) or familial hypercholesterolaemia.
  • Encourage GPs and specialists to state the clinical question the test is intended to answer.
  • Use shared electronic records, secure messaging or written care plans so results reach both the patient’s GP and specialist.
  • Refer eligible patients to public hospital lipid clinics, state-based services or genetic counselling pathways where appropriate.
  • Support professional and patient advocacy that calls for sustainable cardiology and pathology funding across metropolitan, regional and remote Australia.

Better access does not mean ordering every available assay. It means preserving the capacity to identify patients who are most likely to benefit, explain results accurately and provide treatment without unreasonable delays. Clear referral criteria and consistent communication can help services use limited resources where they have the greatest effect.

Patients, GPs, cardiologists and community organisations can strengthen this effort by sharing de-identified experiences with health departments, professional colleges and elected representatives. Evidence about postponed tests, unexpected fees, travel burdens and disrupted follow-up gives policymakers a clearer view of how funding decisions affect real cardiovascular care.

Protecting access to advanced lipid assessment is part of protecting prevention itself. Raise concerns about unexplained costs, ask for a documented care pathway and ensure important lipid results are followed through. In Australia, timely advocacy can help keep specialised cardiovascular risk assessment available to the people and communities who need it most.

A close-up of a handwritten letter on paper beside a pen, warm natural light, soft cream and muted gray tones

Share Your Story

Tell us how Medicare cuts affected access to cardiovascular care. Stories could be reviewed and submitted to local news outlets as part of the campaign's outreach.